Lupin receives approval from USFDA for Bromfenac Ophthalmic
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
The company has new projects in development in Mumbai, Punjab, central and northern India, among others
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
AushadhAI is purposefully designed to deliver significant advantages to the pharmaceutical supply chain's key constituents
Subscribe To Our Newsletter & Stay Updated